Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer
- 340 Downloads
Biochemical markers play a significant role in the diagnosis of lung cancer. Recent studies have demonstrated a link involving S100 Calcium Binding Proteins (S100A2, S100A6) and non-small cell lung cancer (NSCLC), but the expediency of their serum levels in NSCLC has not been established. In this study, we evaluate the potential of serum S100A2 and S100A6 levels as diagnostic markers for NSCLC. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the levels of S100A2 and S100A6 in 141 NSCLC patients and 150 healthy subjects. Serum levels of the two proteins in patients with NSCLC were higher compared to healthy controls (P = 0.0002 for S100A2 and P < 0.0001 for S100A6). Moreover, the levels of S100A2 and S100A6 were higher in the sera of stage I/II NSCLC patients compared to healthy controls with P = 0.01 and <0.0001, respectively. Receiver operating characteristic (ROC) analysis showed that S100A2 could distinguish NSCLC patients from healthy controls (AUC = 0.646), and S100A6 could also identify NSCLC (AUC = 0.668). Meanwhile, these two proteins showed notable capabilities for distinguishing stage I/II NSCLC from healthy controls (AUC = 0.708 for S100A2 and AUC = 0.702 for S100A6). Our results indicate that serum levels of S100A2 and S100A6 are significantly elevated in early stage NSCLC and may have the potential for NSCLC biomarker. Further studies with large sample population would help validate our findings.
KeywordsBiomarkers Calcium binding protein Non-small cell lung cancer S100A2 S100A6
This study was supported by National Natural Science Foundation of China (No. 81302029), Natural Science Foundation of Shaanxi Province of China (No. 2014JQ4149), Fundamental Research Funds for the Central Universities in Xi’an Jiaotong University (No. xjj2015086), and China Postdoctoral Science Foundation (No. 2015 M570841).
Conflicts of interest
- 4.Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, et al. Refining the diagnosis and egfr status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, ttf-1, cytokeratin 5/6, and p63, and egfr mutation analysis. J Thorac Oncol. 2010;5:436–41.CrossRefPubMedGoogle Scholar